Avenue Biosciences: Funding, Investors & Team (Sep 2026)
Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.
Avenue Biosciences has raised $9.9M across 2 funding rounds on record, the most recent a Seed of $7.4M announced in Jan 2026.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Avenue Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Avenue Biosciences Funding Rounds
Avenue Biosciences raised $2.5M in a Seed announced in Oct 2024.
1.3 years later, a Seed of $7.4M was announced in Jan 2026.
Avenue Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Avenue Biosciences Funding Compared to Other Biotechnology Startups
Avenue Biosciences' latest round of $7.4M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Avenue Biosciences in Biotechnology and Palo Alto
Companies Similar to Avenue Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Avenue Biosciences Funding FAQs
What does Avenue Biosciences do?
Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.
How much funding has Avenue Biosciences raised?
Avenue Biosciences has raised $9.9M across 2 rounds on record. The most recent is a Seed of $7.4M announced in Jan 2026.
When did Avenue Biosciences last raise funding?
Avenue Biosciences' most recent funding round on record is a Seed of $7.4M, announced in Jan 2026.
Who founded Avenue Biosciences?
FundedIQ lists Katja Rosti (Founder), Tero Pekka Alastalo (Founder) at Avenue Biosciences.
Where is Avenue Biosciences headquartered?
Avenue Biosciences is based in Palo Alto, California, United States.
How many employees does Avenue Biosciences have?
Avenue Biosciences is in the 11-50 employee band.
How does Avenue Biosciences' funding compare to other Biotechnology startups?
Avenue Biosciences' latest round of $7.4M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Avenue Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Avenue Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.